IBR   13079
INSTITUTO DE BIOLOGIA MOLECULAR Y CELULAR DE ROSARIO
Unidad Ejecutora - UE
artículos
Título:
Aim for the readers! Bromodomains as new targets against Chagas` disease
Autor/es:
ALONSO, VICTORIA LUCIA; CRIBB, PAMELA; ALONSO, VICTORIA LUCIA; CRIBB, PAMELA; PEZZA, ALEJANDRO; SERRA, ESTEBAN CARLOS; PEZZA, ALEJANDRO; TAVERNELLI, LUIS EMILIO; SERRA, ESTEBAN CARLOS; RITAGLIATI, CARLA; TAVERNELLI, LUIS EMILIO; RITAGLIATI, CARLA
Revista:
CURRENT MEDICINAL CHEMISTRY.
Editorial:
BENTHAM SCIENCE PUBL LTD
Referencias:
Lugar: Oak Park; Año: 2018 vol. 25
ISSN:
0929-8673
Resumen:
Bromodomains recognize and bind acetyl-lysine residues present in histone and non-histone proteins in a specific manner. In the last decade they have raised as attractive target for drug discovery because the miss-regulation of human bromodomains was discovered to be involved in the development of a large spectrum of diseases. However, targeting eukaryotic pathogens bromodomains continues to be almost unexplored. We and others have reported the essentiality of diverse bromodomain-containing proteins in protozoa, offering a new opportunity for the development of antiparasitic drugs, especially for Trypansoma cruzi, the causative agent of Chagas´ disease. Mammalian bromodomains were classified in eight groups based on sequence similarity but parasitic bromodomains are very divergent proteins and is hard to assign them to any of these groups, suggesting that selective inhibitors can be obtained. In this review we describe the importance of lysine acetylation and bromodomains in T. cruzi as well as the current knowledge on mammalian bromodomains. Also, we summarize the myriad of small-molecules under study to treat different pathologies and which of them have been tested in trypanosomatids and other protozoa. All the information available led us to propose that T. cruzi bromodomains should be considered as important potential targets and the search for small-molecules to inhibit them should be empowered.